Intra-Cellular Therapies
Latest round
- Series C
Last raised
- Oct 2007
Total raised
- $14M
Investors
- 3
About Intra-Cellular Therapies
Based in New York, US, and founded by Sharon Mates (Chairman and CEO) in 2001, Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company developing target mechanism to counter the progression of Alzheimer's Disease.14 million shares on the NASDAQ.52 million shares on the NASDAQ. The firm trades under the ticker symbol ITCI. In January 2025, Johnson & Johnson, Inc. agreed to fully acquire Intra-Cellular Therapies, Inc.6 billion. The company’s flagship product, CAPLYTA® (lumateperone), is FDA-approved for treating schizophrenia and bipolar depression, offering a unique mechanism of action that combines efficacy with a favorable safety profile. Intra-Cellular Therapies' pipeline includes: ITI-1284 ODT-SL for generalized anxiety and agitation in Alzheimer’s patients, ITI-333 for opioid use disorder and mood disorders, and the ITI-1500 series, featuring non-hallucinogenic psychedelics aimed at mood disorders. In addition to these, the company is advancing PDE1 inhibitors like lenrispodun (ITI-214) for Parkinson’s disease and ITI-1020 for cancer immunotherapy.
Who invested in Intra-Cellular Therapies
3 investors across 2 rounds
See all investors in Intra-Cellular Therapies
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Intra-Cellular Therapies
Who invested in Intra-Cellular Therapies?
Intra-Cellular Therapies has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Intra-Cellular Therapies raised?
Intra-Cellular Therapies has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Intra-Cellular Therapies last raise money?
Intra-Cellular Therapies's most recent round on record is a Series C, in Oct 2007.
What does Intra-Cellular Therapies do?
Based in New York, US, and founded by Sharon Mates (Chairman and CEO) in 2001, Intra-Cellular Therapies, Inc.
Where is Intra-Cellular Therapies headquartered?
Intra-Cellular Therapies is headquartered in Bedminster, US.
Which VCs invest in companies like Intra-Cellular Therapies?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Intra-Cellular Therapies's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Intra-Cellular Therapies? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.